MX2007007206A - Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos. - Google Patents

Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos.

Info

Publication number
MX2007007206A
MX2007007206A MX2007007206A MX2007007206A MX2007007206A MX 2007007206 A MX2007007206 A MX 2007007206A MX 2007007206 A MX2007007206 A MX 2007007206A MX 2007007206 A MX2007007206 A MX 2007007206A MX 2007007206 A MX2007007206 A MX 2007007206A
Authority
MX
Mexico
Prior art keywords
agonist
prevention
treatment
neurodegenerative disorders
patient
Prior art date
Application number
MX2007007206A
Other languages
English (en)
Spanish (es)
Inventor
Margaret Maria Zaleska
Lee Erwin Schechter
Kevin Pong
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2007007206A publication Critical patent/MX2007007206A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2007007206A 2004-12-14 2005-12-12 Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos. MX2007007206A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63576604P 2004-12-14 2004-12-14
PCT/US2005/044820 WO2006065710A1 (en) 2004-12-14 2005-12-12 Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
MX2007007206A true MX2007007206A (es) 2008-03-26

Family

ID=36177731

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007206A MX2007007206A (es) 2004-12-14 2005-12-12 Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos.

Country Status (15)

Country Link
US (1) US20060128744A1 (cg-RX-API-DMAC7.html)
EP (1) EP1824464A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008523146A (cg-RX-API-DMAC7.html)
KR (1) KR20070088770A (cg-RX-API-DMAC7.html)
CN (1) CN101098683A (cg-RX-API-DMAC7.html)
AU (1) AU2005316675A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0519036A2 (cg-RX-API-DMAC7.html)
CA (1) CA2590841A1 (cg-RX-API-DMAC7.html)
CR (1) CR9200A (cg-RX-API-DMAC7.html)
IL (1) IL183859A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007007206A (cg-RX-API-DMAC7.html)
NO (1) NO20073104L (cg-RX-API-DMAC7.html)
RU (1) RU2007122450A (cg-RX-API-DMAC7.html)
WO (1) WO2006065710A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200705083B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200301251A (en) * 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
JP2005305107A (ja) * 2004-03-25 2005-11-04 Sei Matsuoka 価値的情報値の測定装置およびこれを使用した測定方法
CA2858520A1 (en) 2006-05-18 2007-11-29 Pharmacyclics Inc. Intracellular kinase inhibitors
EP1953153A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
CN104276993B (zh) * 2013-07-12 2019-03-15 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
CN104557664B (zh) * 2013-10-19 2020-01-21 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
DE60213856T2 (de) * 2001-12-20 2007-09-13 Wyeth Indolylalkylamin-derivate als 5-hydroxytryptamin-6 liganden
UA78999C2 (en) * 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6

Also Published As

Publication number Publication date
ZA200705083B (en) 2010-03-31
BRPI0519036A2 (pt) 2008-12-23
AU2005316675A1 (en) 2006-06-22
CR9200A (es) 2007-09-07
WO2006065710A1 (en) 2006-06-22
US20060128744A1 (en) 2006-06-15
KR20070088770A (ko) 2007-08-29
CA2590841A1 (en) 2006-06-22
EP1824464A1 (en) 2007-08-29
NO20073104L (no) 2007-07-02
IL183859A0 (en) 2008-12-29
JP2008523146A (ja) 2008-07-03
RU2007122450A (ru) 2009-01-27
CN101098683A (zh) 2008-01-02

Similar Documents

Publication Publication Date Title
TW200602048A (en) Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase
IL182417A0 (en) Mitotic kinesin inhibitors and methods of use thereof
TW200602045A (en) Amino-5, 5-diphenylimidazolone derivatives for the inhibition of β-secretase
TW200612926A (en) Compounds and compositions as ppar modulators
MX2010003117A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
MY162067A (en) Combination therapy for treatment of patients with neurological disorders and cerebral infarction
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
IL186707A (en) Mitotic quinine inhibitors and medical preparations containing them
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
NO20073104L (no) Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2004093813A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
UA96926C2 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
PT1567139E (pt) Nova combinação sinérgica compreendendo roflumilaste e formoterol
WO2005092062A3 (en) Compounds for neurodegenerative disorders
MX2010003615A (es) Tratamiento de desordenes neurologicos.
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
TNSN06382A1 (en) Compounds and compositions as ppar modulators
TW200635580A (en) Methods of treatment and prevention
ATE468852T1 (de) Lofexidine zur intraspinalen anwendung